Clinical Trial Detail

NCT ID NCT02522715
Title Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

prostate cancer

Therapies

Cabazitaxel + Enzalutamide

Prednisone

Age Groups: adult

No variant requirements are available.